New England District Update FDA s Office of Regulatory Affairs Aligns for the Future
|
|
|
- Angelica Elinor Bell
- 6 years ago
- Views:
Transcription
1 New England District Update FDA s Office of Regulatory Affairs Aligns for the Future MassMedic December 12, 2017 Waltham, MA Joseph S. Matrisciano Jr, JD, PE Director, New England District Director, Office of Medical Products and Radiological Health Operations Division 1
2 2
3 FDA S OFFICE OF REGULATORY AFFAIRS ALIGNS FOR THE FUTURE MODERNIZE AND STRENGTHEN THE FDA WORKFORCE TO IMPROVE PUBLIC HEALTH RESPONSE FDA PROGRAM ALIGNMENT CHARGE 3
4 ORA Program Divisions Office of Bioresearch Monitoring Operations (OBIMO) Office of Biological Products Operations (OBPO) Office of Medical Device and Radiological Health Operations (OMDRHO) Office of Pharmaceutical Quality Operations (OPQO) Office of Human and Animal Food Operations (OHAFO) Office of Enforcement and Import Operations (OEIO) Tobacco Operations Program 4
![and Tobacco Operations Director Tobacco Staff [vacant]](/docs-images/75/71682369/images/5-5.jpg "Ginette Michaud, MD Director, Office of Biological Products")
5 Office of Medical Products and Tobacco Operations Ellen Morrison Assistant Commissioner Office of Medical Products and Tobacco Operations Director Tobacco Staff [vacant] Ginette Michaud, MD Director, Office of Biological Products Operations Chrissy Cochran, PhD Director, Office of Bioresearch Monitoring Operations Jan Welch Director, Office of Medical Device and Radiological Health Operations Alonza Cruse Director, Office of Pharmaceutical Quality Operations 5
6 6
7 Office of Medical Device and Radiological Health Operations Jan Welch Director, Office of Medical Device and Radiological Health 7
8 Office of Medical Device and Radiological Health Operations 8
9 9
10 New England District Domestic Inventory ,049 4,057 3,395 Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) Center for Veterinary Medicine (CVM) Center for Drugs Evaluation and Research (CDER) Center for Food Safety and Applied Nutrition (CFSAN) 10
11 NWE-DO/MDRHE Accomplishments FY 17 From 10/1/16 5/14/17 for New England states only Completed 78 domestic medical device inspections From 5/15 9/30/17 for MDRHE Completed 188 domestic medical device inspections 11
12 FY 17 FDA-483 Observations Top 5 medical device observations nationally 1. Inadequate establishment of CAPA procedures, 21 CFR (a) 2. Inadequate establishment of complaint procedures, 21 CFR (a) 3. Inadequate process validation, 21 CFR (a) 4. Inadequate purchasing controls, 21 CFR Inadequate MDR procedures, 21 CFR
13 Compliance Actions Domestic FY17 Warning Letters FY 17 NWE WL s (10/1/16 5/14/17) 9 total 4 device FY 17 MDRHE WL s (5/15 9/30/17) 3 device Reg Meetings FY 17 NWE - 1 device FY 17 MDRHE 3 device Injunctions
14 IMPORT LINES - NATIONWIDE (FY17) CDRH (49%) CFSAN (47%) CDER (2%) CVM (1%) CTP (< 1%) CBER (< 1%) 14
15 IMPORT LINES NWE-DO (FY17) CFSAN (55%) CDRH (38%) CVM (5%) CDER (2%) CBER (< 1%) CTP (< 1%) 15
16 TOP TEN CDRH IMPORTED PRODUCTS FY17 ALL DISTRICTS 2,500,000 2,000,000 1,500,000 1,000, ,000 0 Surgical Drape Surgical Gown Piston Syringe (KKK) (FYA) (FMF) Scalpel Blade (GES) Nonabsorable Gauze (GDY) Emesis Basin (FNY) Protective Electrosurgical Barrier Cover Device (GEI) (MMP) Hypodermic Needle (FMI) Absorbent Medical Fiber (FRL) 16
17 TOP TEN CDRH IMPORTED PRODUCTS FY17 NWE-DO 25,000 20,000 15,000 10,000 5,
18 Shipments by Country of Origin Imports FY17 (NWE-DO) TOTAL LINES: 673,050 DEVICE LINES: 258,414 39% Canada 29% GERMANY 12% Germany 27% SWITZERLAND 11% Switzerland 15% IRELAND 18
19 Final Admissibility Decisions Imports FY17 (NWE-DO) DECISION ALL LINES DEVICE LINES May-Proceeds 663, ,507 Releases 4, Releases after Detention Refusals TOTALS: 669, ,842 19
20 Compliance Actions Imports FY17 (NWE-DO) 48 total Import Alert (IA) recommendations for NWE-DO ports of entry IAs provide guidance to the field that FDA has sufficient evidence to Detain Without Physical Examination (DWPE). 7 of these recommendations were related to device/electronic products and for the following alerts: 20
21 Import Alerts FY17 (NWE-DO) Import Alert 80-04, Surveillance and DWPE of Surgeon s and Patient Examination Gloves (three cases) Import Alert 89-08, DWPE of Class III Devices Without Approved PMA's or IDE's and Other Devices Not Equivalent or No 510k (two cases) Import Alert 89-17, DWPE of Medical Devices that appear to be adulterated because their quality falls below that which they purport or are represented to possess Import Alert 95-05, DWPE of Electronic Products that fail to comply with Performance Standards or no certification 21
22 NWE/MDRHE FY 2017 Recalls From 10/1/16 5/14/17 for New England states only and from 5/15 9/30/17 for MDRHE 152 Device 6 Class I 103 Class II 5 Class III 3 Market Withdrawal 22
23 Device Recalls FY 17 Examples Class I Lead Blood Test Kits, underestimates the lead concentration of venous blood samples. Class II Patient monitoring cable, manufacturing defect may cause localized heating, which may result in localized skin burn. Class III Fluorometer, for clinical use, potential plate loading failures. 23
24 Office of Medical Device and Radiological Health Operations Immediate Office Office Title Name OMDRHO Director Jan Welch OMDRHO Deputy Director Anne Reid OMDRHO Special Assistant Kristina Donohue OMDRHO QMS Manager Lynne Dwyer OMDRHO Training Officer Monica Forrest OMDRHO/Medical Device and Radiological Health Staff Operations OMDRHO/Foreign Medical Devices and Radiological Health Inspection Staff Staff Director Staff Director Rhonda Mecl (Acting) Dorothy Lee 24
25 Office of Medical Device and Radiological Health Operations Division I Office Title Name Coverage OMDRHO Division I Division Director/Program Division Director Joseph S. Matrisciano Jr NWE/BLT/CIN/DET/NWJ/NYK/PHI OMDRHO Division I Compliance Branch Director Gina Brackett (Acting) NWE/BLT/CIN/DET/NWJ/NYK/PHI OMDRHO Division I Investigations Branch Director Arduino Frankovic NWE/BLT/CIN/DET/NWJ/NYK/PHI 25
26 Office of Medical Device and Radiological Health Operations Division II Office Title Name Coverage OMDRHO Division II Program Division Director Kathleen Sinninger (Acting) FLA/ATL/CHI/KAN/MIN/NOL/SJN OMDRHO Division II Compliance Branch Director Blake Bevill FLA/ATL/CHI/KAN/MIN/NOL/SJN OMDRHO Division II Investigations Branch Director Travis Chapman (Acting) FLA/ATL/CHI/KAN/MIN/NOL/SJN 26
27 Office of Medical Device and Radiological Health Operations Division III Office Title Name Coverage OMDRHO Division III Program Division Director Shari Shambaugh (Acting) LOS/DAL/DEN/SAN/SEA OMDRHO Division III Compliance Branch Director Kelly Sheppard LOS/DAL/DEN/SAN/SEA OMDRHO Division III Investigations Branch Director Eric Anderson (Acting) LOS/DAL/DEN/SAN/SEA 27
28 ORA Ombudsman Informally and impartially addresses concerns, complaints, and disputes between ORA and external parties: Industry Federal, state, territory, and tribal government entities Public Contact: or Jessica Zeller, JD, MA Ombudsman PUBLIC HEALTH PARTNERSHIPS: Enhancing ORA operations by serving as an objective, neutral resource to improve communication channels, resolve disputes, and foster positive relationships with internal and external stakeholders. 28
29 What s Next Complete the structural changes Continue to advance operational change (e.g.) Updated training programs & subspecialties Revamp work planning National operations SOPs Continuous Improvement 29
30 Resources and Contacts ORA Organization Charts and Boundary Maps Fact Sheets ORA s New Structure Operational Offices Investigations Operations Manual Headquarters, District/Division Contact Information ORA Contacts State and local inquiries District Director/Program Division Directors State Liaison General Inquiries engageora@fda.hhs.gov Partnerships OP-ORA@fda.hhs.gov 30
31 OMDRHO Division Inspectional Handouts Division 1: Resources and Contacts Division 2: Division 3: Presenter: Joe Matrisciano Telephone:
32
33
PROGRAM ALIGNMENT AND IMPACT FOR INSPECTIONS
FDA S OFFICE OF REGULATORY AFFAIRS PROGRAM ALIGNMENT AND IMPACT FOR INSPECTIONS ELLEN MORRISON, ASSISTANT COMMISSIONER FOR MEDICAL PRODUCTS AND TOBACCO PROGRAMS 12TH ANNUAL FDA INSPECTIONS SUMMIT NOVEMBER
BIMO Program Update an operational perspective
BIMO Program Update an operational perspective Clinical Trials Summit San Juan, Puerto Rico May 9, 2018 Anne E. Johnson Program Division Director FDA/ORA/OBIMO Division I (East) 1 Objectives Program Alignment
FDA S OFFICE OF REGULATORY AFFAIRS ALIGNS FOR THE FUTURE
FDA S OFFICE OF REGULATORY AFFAIRS ALIGNS FOR THE FUTURE 121ST AFDO EDUCATIONAL CONFERENCE June 19, 2017 1 Modernize and strengthen the FDA workforce to improve public health response. 2013 FDA Program
LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.
LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S. Food and Drug Administration 1 Office of the Commissioner
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
Chapter 48 - Bioresearch Monitoring
COMPLIANCE GUIDANCE MANUAL Chapter 48 - Bioresearch Monitoring Subject SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS Implementation Date February 21, 2001 Completion Date Continuing Product Codes
2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
US FOOD and DRUG ADMINISTRATION
US FOOD and DRUG ADMINISTRATION FDA Presentation on Los Angeles District Import Operations May 17, 2011 Dan Solis, Director of Import Operations Los Angeles District Office 1 Cabinet of the United States
FDA s Office of Regulatory Affairs Aligns for the Future
FDA s Office of Regulatory Affairs Aligns for the Future Jennifer Thomas Acting, ORA Office of Enforcement and Import Operations December 2017 Modernize and strengthen the FDA workforce to improve public
Update on FSMA Implementation. Rebecca Buckner May 24, 2016
Update on FSMA Implementation Rebecca Buckner May 24, 2016 Presentation Overview FSMA Implementation Rulemaking and Industry Guidance - Focus on the Preventive Controls Rules FSMA Implementation Guiding
Chapter 21. FDA Inspections
Chapter 21 FDA Inspections Jennifer M. Thomas & Douglas B. Farquhar 21:1 Role of Inspections 21:1.1 Overview 21:1.2 FDA s Reasons to Inspect 21:1.3 Potential Outcomes of Inspections 21:2 FDA Authority
FDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations
FDA Inspectional Process in Clinical Research An FDA Perspective Annette Melendez, MPHsN Investigator Office of Biological Products Operations Outline BIMO PROGRAM OVERVIEW PROGRAM COVERED AREAS INSPECTIONAL
Introduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER Sara Camilli, PharmD, BCPS, Safety Evaluator Team Leader Selena Ready, PharmD, CGP, Safety Evaluator Division of Pharmacovigilance
Postmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
Solutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
Solutions for GCP Compliance Challenges
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
FDA. Office of Criminal Investigations
FDA Office of Criminal Investigations Established in March 1992 by the Commissioner, with the urging of Congress, in response to concerns of increased criminal violations of the Act 1 OCI Mission Statement
Investigator Roles and Responsibilities in Clinical Device Trials
Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and
SJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office
SJN DO CB Field Alert Reports Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office SJN DO Mission Assuring that safe and effective drugs are available to the public
FSMA User Guide. Food Safety Modernization Act Guide
Food Safety Modernization Act Guide The Food Safety Modernization Act of 2011 (FSMA), the first major overhaul of food safety legislation in more than 70 years, gives FDA the new job of building a modern,
Connie Hoy October 2013
Connie Hoy October 2013 Warning letter issued to firm for complaint handling Failure to report within 30 days Failure to implement adequate procedures Failure to establish standard review process No procedure
FSMA Implementation FDA s Preventive Controls Rules
FSMA Implementation FDA s Preventive Controls Rules 2016 National Association of Dairy Regulatory Officials Annual Meeting July 11, 2016 CAPT Robert (Bob) Hennes, MST Leader Presentation Overview FSMA
:,-, WARNING LETTER. Mr. Jean Claude Mas Chief Executive Officer Poly Implants Protheses, Sa 337 Avenue De Bruxelles La Seyne, Sur Mer France
+., %- *: $1.,X,, *,+,,r + $, DEPARTMENT +, %, >,,, :,-, OF HEALTH & HUMAN SERVICES Public Health Service VIA FEDERAL EXPRESS ~ 22moo WARNING LETTER Mr. Jean Claude Mas Chief Executive Officer Poly Implants
FDA Reauthorization Act of 2017 (FDARA)
FDA Reauthorization Act of 2017 (FDARA) April 4, 2018 PRESENTED BY: Jessica Ringel Counsel FDA & Life Sciences Practice Group King & Spalding LLP (202) 626-9259 jringel@kslaw.com FDA Reauthorization Act
Complaint Handling and Medical Device Reporting (MDRs)
Complaint Handling and Medical Device Reporting (MDRs) FDA Small Business Regulatory Education for Industry (REdI) Bethesda, MD September 26, 2013 Andrew Xiao Consumer Safety Officer, Postmarket and Consumer
FDA s Clinical Trial Inspections in China Including FDA Overall Goals
FDA s Clinical Trial Inspections in China Including FDA Overall Goals Prepared for You by Barbara Kephart Immel, President, Immel Resources LLC 2013, Immel Resources LLC 1 Overview Budget China Initiative
Medical Device Recall Report FY FY 2012
Medical Device Recall Report FY 2003- FY 2012 Ann Ferriter Division of Analysis and Program Operations Office of Compliance Center for Devices and Radiological Health Questions Why did FDA draft the Medical
1. Review the scenario, resource list, and scenario map in your handouts.
Unit 2. ICS Fundamentals INSTRUCTOR NOTES UNIT 2: PET FOOD RECALL SCENARIO Objective: To review the key concepts of ICS. Instructions: Ask the participants to work in teams to complete the following activity:
Patient Involvement at
Patient Involvement at Andrea Furia-Helms, MPH FDA Patient Representative Program Office of Health and Constituent Affairs Food and Drug Administration (FDA) White Oak Campus Silver Spring, Maryland FDA
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update Ginger M. Sykes Supervisory Consumer Safety Officer Salt Lake City Resident Post Office of Regulatory Affairs U.S. Food and
. s%rwcu ~,+ *+ % %vd3a 7 Food and Drug Administration. Center for Devices and
* %. s%rwcu ~,+ *+ Jf ~ DEPARTMENT OF HEAITH & HUMAN SERVICIB Public Health Setvice z 2 4/5924 % % %vd3a 7 Food and Drug Administration. Center for Devices and Radiological 2098 Gaither Road Via Federal
WIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
The FDA Food Safety Modernization Act of 2009 Section-by-Section Summary
The FDA Food Safety Modernization Act of 2009 Section-by-Section Summary Title I Improving Capacity to Prevent Food Safety Problems Sec. 101. Inspection of Records Gives FDA expanded access to food facility
Data Acceptance Panel Discussion
OFFICE OF FOODS AND VETERINARY MEDICINE Data Acceptance Panel Discussion January 31, 2018 4 th Governmental Food and Feed Laboratory Accreditation Meeting The FDA Foods Veterinary Medicine Program and
Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements
Guidance for Industry and FDA Staff Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements Document Issued on: February 28, 2008
FDA SEATTLE DISTRICT REGULATORY UPDATE
FDA SEATTLE DISTRICT REGULATORY UPDATE SEAFOOD PRODUCTS ASSOCIATION PROCESSORS WORKSHOP SEATTLE, WASHINGTON MARCH 10, 2015 MIRIAM R. BURBACH SEATTLE DISTRICT DIRECTOR 1 FDA SEATTLE DISTRICT REGULATORY
Inspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Husain, Mustafa M, M.D. 23-Jul-08 Department of Health and Human Services Public Health Service Food and Drug Administration Center for
Session 3 FDA Audits and Findings
Session 3 FDA Audits and Findings Byungja Marciante, Investigator US Food and Drug Administration Shanghai Centre-Suite 723 1376 Nanjing Xi Lu Shanghai, PRC 200040 美国食品药品管理局上海商城 723 室南京西路 1376 号中国上海 200040
Establishment of the FDA Office of Patient Affairs
Establishment of the FDA Office of Patient Affairs Policy Proposal: With the advent of new and innovative patient engagement programs within the Food and Drug Administration (FDA), a growing need for greater
Regulatory Submissions Trends Survey 2002 Ellen Semple Date received (in revised form): 18th March, 2003
Ellen Semple joined CDC Solutions in July 2002 and is VP of Global Marketing. She oversees the strategic direction of CDC Solutions global marketing teams and works directly with CDC s work headquarters
Food Safety Modernization Act
Aon Risk Solutions Food Safety Modernization Act Highlights and Implications for Your Business Risk. Reinsurance. Human Resources. On January 4, 2011, President Obama signed the Food Safety Modernization
PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK. Marian Boardley 2013
PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK Marian Boardley 2013 APPLICABLE GMP S: DIETARY SUPPLEMENT LABS Subparts for laboratory operations and testing, 21 CFR 111 D Equipment
Draft Guidance for Industry on Part 11, Electronic Records, Electronic. Signatures Scope and Application; Availability of Draft Guidance and
1 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket Nos. 03D 0060, 99D 1458, 00D 1538, 00D 1543, 00D 1542, and 00D 1539] Draft Guidance for Industry on Part 11, Electronic Records,
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
May 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).
L A W O F F I C E S 7 0 0 T H I R T E E N T H S T R E E T, N. W. S U I T E 1 2 0 0 W A S H I N G T O N, D. C. 2 0 0 0 5-5 9 2 9 ( 2 0 2 ) 7 3 7-5 6 0 0 F A C S I M I L E ( 2 0 2 ) 7 3 7-9 3 2 9 w w w.
FDA HAS MADE PROGRESS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA HAS MADE PROGRESS ON OVERSIGHT AND INSPECTIONS OF MANUFACTURERS OF GENERIC DRUGS Daniel R. Levinson Inspector General May 2015 OEI-01-13-00600
Update on Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care
Update on Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care Terrell Cunningham, BSN, RN Scientific Reviewer, Team Leader Personal Protective Equipment Infection Control
Food Safety Protocol, 2016
Ministry of Health and Long-Term Care Food Safety Protocol, 2016 Population and Public Health Division, Ministry of Health and Long-Term Care May 2016 Preamble The Ontario Public Health Standards (OPHS)
Guidance for Industry and Food and Drug Administration Staff
Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff Document
Bristol Myers Squibb Holdings Pharma., Ltd.
Bristol Myers Squibb Holdings Pharma., Ltd. Department of Health and Human Services Public Health Service Food and Drug Administration 466 Fernandez Juncos Avenue Puerta De Tierra San Juan, Puerto Rico
MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review
Page 1 MDUFA Performance Goals and Procedures... 3 I. Process Improvements... 3 A. Pre-Submissions... 3 B. Submission Acceptance Criteria... 4 C. Interactive Review... 5 D. Guidance Document Development...
SPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS
SPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS Food and Drug Administration Center for Devices and Radiological Health Office of Compliance Division of Bioresearch Monitoring Doreen Kezer,
Deeper Dive of the Preventive Controls for Human Food Rule in Produce Packing Facilities
Overview of FSMA Rules: Preventive Controls GA Watermelon Association September 19, 2016 Produce Food Safety Services GA Fruit & Vegetable Growers Association Deeper Dive of the Preventive Controls for
Assessment of the FDA Rapid Response Team s Implementation
Assessment of the FDA Rapid Response Team s Implementation Brenda D. Morris IFPTI 2011 Fellow Florida Dept. of Agriculture and Consumer Services Division of Food Safety Slide 1 Background Increased national
Pediatric Medical Device Development and Safety. Jacqueline N. Francis, MD, MPH Medical Officer, PSRB, ODE, CDRH, FDA
Pediatric Medical Device Development and Safety Jacqueline N. Francis, MD, MPH Medical Officer, PSRB, ODE, CDRH, FDA This presentation represents the professional opinion of the speaker and is not an official
ADVANCED PLASTIC SURGERY, PLLC. NOTICE OF PRIVACY PRACTICES
Effective Date: July 1 st 2013 ADVANCED PLASTIC SURGERY, PLLC. NOTICE OF PRIVACY PRACTICES THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO
The Mammography Quality Standards Act Final Regulations Quality Assurance Documentation
Compliance Guidance The Mammography Quality Standards Act Final Regulations Quality Assurance Documentation Document issued on December 7, 1999 U.S. Department Of Health And Human Services Food and Drug
The University of Chicago Medicine Privacy Program Accounting of Disclosures Definition Table
The HIPAA Privacy Rule provides an individual with the right to receive a listing, known as an Accounting of s, which provides information about when the University of Chicago Medicine (UCM) discloses
Received an RTA Deficiency List or AI Letter? Now What?
Received an RTA Deficiency List or AI Letter? Now What? Dealing with Unexpected Issues/Questions during the Submission Review Process Navigating Submission Challenges to reduce time & risk September 26,
DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: August 5, 2008
Draft Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff Humanitarian Device Exemption (HDE) Regulation: Questions and Answers DRAFT GUIDANCE This guidance
The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements
The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements Beatrice Moreau Senior Regulatory Advisor Registrar Corp 144 Research Drive Hampton, Virginia USA 23666
STANDARDIZED PROCEDURE CENTRAL LINE PLACEMENT and TEMPORARY NONTUNNELLED CENTRAL VENOUS DIALYSIS CATHETER INSERTION (Adult, Peds)
I. Definition: This protocol covers the task of central (venous) catheter placement and temporary nontunnelled central venous dialysis catheters by the Advanced Health Practitioner. The purpose of this
FDA Office of Partnerships
FDA Office of Partnerships Guy F. Delius, R.S. FDA-OP Standards Implementation Staff AFDOSS September 8, 2014 1 Cooperation & Collaboration: A daily priority for the FDA We will strengthen our collaborations
CDRH Device Quality Update March 17, 2015
CDRH Device Quality Update March 17, 2015 William C. MacFarland FDA/CDRH/OC/Division of Manufacturing and Quality 1 Agenda Themes for 2015 FDA Commissioner s Program Alignment FDA s Case for Quality 2015
MEDICAL PROCEDURES PRACTICAL EXAM EVALUATION FORM 2001
MEDICAL PROCEDURES PRACTICAL EXAM EVALUATION FORM 2001 STUDENT NAME: Station One: Sterile Technique and Skin Preparation Instructor: Nelson Kraus Syringes with needles Alcohol pads Water in multi-dose
Audits/Inspections Be Prepared for Anything
Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary
Guidance for Industry
Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Inspections, Compliance, Enforcement, and Criminal Investigations
1 of 5 2/11/2014 11:24 AM Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Baxter
Authorized Personnel to Review
October 31, 2017 Page 1 of 7 All documents developed or maintained for the Manufactured Food Regulatory Program Standards ( MFRPS ) are listed below. For each document, the following information is included:
Review of Existing Center for Drug Evaluation and Research Regulatory and Information
This document is scheduled to be published in the Federal Register on 09/08/2017 and available online at https://federalregister.gov/d/2017-19033, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
FSMA Update. Samantha Shinbaum. October 3, 2017
FSMA Update Samantha Shinbaum October 3, 2017 Background Information A Little About Me Received my Bachelors from the University of Florida. Received my Masters from the University of Arkansas. Working
Coalition of Food Protection Task Forces Virtual Conference Coalition Building for Integration
Coalition of Food Protection Task Forces Virtual Conference Coalition Building for Integration March 8th 2018, Thursday, 1:30-3:30 PM EST 1:30 pm 3:30 pm Moderator Thanh Andrews, Project Officer,, FL 1:30
BE-595M Homework Assignment Due: 3/3/08
BE-595M Homework Assignment Due: 3/3/08 Attached is a Warning Letter issued to Applied Water Engineering, Inc., Salt Lake City, UT, for violations of the Quality System Regulations. The firm manufactures
Medical Devices: Do I Need to Open a CAPA?
Medical Devices: Do I Need to Open a CAPA? Adrienne Franco Busby, Partner, Faegre Baker Daniels LLP Anne Miller, Principal Regulatory Counsel, Medtronic Marta L. Villarraga, Principal, Exponent, Inc. Moderated
+.,m 7. yw ~ ~ & DEC FEDERAL EXPRESS
+,*,s WC, ~ *4+ S* DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service, % %,+ 747 +,m 7 Food and Drug Administration 5 Jg FEDERAL EXPRESS 2088 Gaither Road Rockville MD 20850 yw ~ ~ & 4 DEC 21997
FDA INSPECTIONS SUMMIT
PRESENTS THE #1 EVENT FOR QUALITY, COMPLIANCE AND INSPECTIONAL READINESS PROFESSIONALS SUMMIT CO-CHAIRS: NOVEMBER 1-3, 2017 DOUBLETREE BETHESDA BETHESDA, MD (WASHINGTON, DC) 2017 SUMMIT HIGHLIGHTS NEW
U.S. - EC MRA Pharmaceutical Good Manufacturing Practices Annex. SECTORAL ANNEX FOR PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) CHAPTER 1
SECTORAL ANNEX FOR PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) PREAMBLE This Annex constitutes a Sectoral Annex to the Agreement on Mutual Recognition between the United States and the European
FDA Inspection Readiness
FDA Inspection Readiness Richard Angelo, Ph.D. Director, Managing Consultant October 17, 2014 Agenda Reasons for Inspections Preparing for Inspections Inspection Day Inspection Outcomes 2013 Inspection
WARNING LETTER VIA FEDERAL EXPRES S
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EPRES S George W. LeMaitre Chairman
Safe at Work Ontario. Ronald Landry (A) Provincial Coordinator, Industrial Health & Safety Program Operations Division
Safe at Work Ontario Ronald Landry (A) Provincial Coordinator, Industrial Health & Safety Program Operations Division Annual Petrochem Forum June 14, 2018 June 12, 2018 Allowed Lost Time Injury Rates by
Clinical Research Professionals
Training & Resources for Clinical Research Professionals Course & Publications Catalog January July 2016 In-Person and Web-Based Training Courses, Customized Training, elearning and Publications for Clinical
FDA Outlook Seth A. Mailhot, Partner Lead, FDA Regulatory Practice
FDA Outlook 2017 Seth A. Mailhot, Partner Lead, FDA Regulatory Practice January,25, 2017 Overview Gaming the Elections Influence on FDA in 2017 Potential Congressional Activity PDUFA VI and MDUFA IV Restructuring
FSMA Enforcement: The First Year
FSMA Enforcement: The First Year Scott J. MacIntire Director, Division of Enforcement FDA Office of Regulatory Affairs December 6, 2017 Topics to Include Compliance & Enforcement FSMA Inspections Human
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 JUL 1 3 2CG3 WARNING LETTER Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS In August 2010, the Food and Drug Administration s Center for Devices and Radiological Health (CDRH or the Center) released for public
Establishment Registration and Device Listing. Michelle C. Jackson, Esq. Partner Venable LLP
Establishment Registration and Device Listing Michelle C. Jackson, Esq. Partner Venable LLP Learning Objectives Statutory Basis for Registration and Listing Relevant Regulations Who Must Register and List
Delegation Agreement Between and. Minnesota Department of Health
Delegation Agreement Between and Minnesota Department of Health This Agreement, effective on the first day of, 20, is between the State of Minnesota acting through its Commissioner of Health ( Minnesota
Division of Federal-State Relations. Food Safety Modernization Act
Food Safety Modernization Act Joe Reardon, Director, Division of Federal-State Relations Association of American Feed Control Officials July 30, 2011 Main Themes of the Legislation Prevention Standards
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
60-4 (v4 ( ~' DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service. Food and Drug Administration 9200 Corporate Boulevard el Rockville, Maryland 20850 MAY - 6 2008 VIA FEDERAL EXPRES S Merrill W.
Medical Device Reporting. FD&C Act CFR Direct Final Rule 2/28/05. As amended by:
Medical Device Reporting Direct Final Rule 2/28/05 FD&C Act 519 As amended by: Safe Medical Devices Act of 1990 Medical Device Amendments of 1992 FDA Modernization Act of 1997 Authority to require manufacturers,
Defense Logistics Agency INSTRUCTION VETERINARY MEDICAL AND INSPECTION OF SUBSISTENCE SUPPLIES AND SERVICES
Defense Logistics Agency INSTRUCTION DLAI 3221 Effective Date: August 2013 SUBJECT: VETERINARY MEDICAL AND INSPECTION OF SUBSISTENCE SUPPLIES AND SERVICES REFERENCES: See Enclosure 1. 1. PURPOSE. This
Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors. Exception from Informed Consent Requirements for Emergency Research
Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors Exception from Informed Consent Requirements for Emergency Research U.S. Department of Health and Human Services Food and
LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS
LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH
Regulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center
Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical
Standards and Medical Device Regulation Roundtable. Seoul South Korea. 21 October ASTM International
Standards and Medical Device Regulation Roundtable Seoul South Korea 21 October 2014 FDA s Use of Voluntary Consensus Standards Scott Colburn, Director CDRH Standards Program Office of the Center Director,
NEW JERSEY. Downloaded January 2011
NEW JERSEY Downloaded January 2011 SUBCHAPTER 29. MANDATORY PHARMACY 8:39 29.1 Mandatory pharmacy organization (a) A facility shall have a consultant pharmacist and either a provider pharmacist or, if
Draft 11/3/2017. Crosswalk - Requirements for Foodborne Illness Training Programs Based on Standard 5
Draft 11/3/2017 Crosswalk - Requirements for Training Programs Based on Standard 5 Introduction: The 2012 2014 Interdisciplinary Training Committee (IFITC) obtained the Food Safety and Modernization Act
Crosswalk - Requirements for Foodborne Illness Training Programs Based on Standard 5
Crosswalk - Requirements for Training Programs Based on Standard 5 Introduction: The 2012 2014 Interdisciplinary Training Committee (IFITC) obtained the FSMA 205 C(1) Phases of a Food Incident (CIFOR/RRT/MFRPS/VNRFRPS
U.S. Food and Drug Administration Office of Acquisitions & Grants Services (OAGS)
U.S. Food and Drug Administration Office of Acquisitions & Grants Services (OAGS) Montgomery County Chamber of Commerce OAGS OVERVIEW Who we are What we buy How we operate OAGS Mission Our mission is to
Institutional Handbook of Operating Procedures Policy
Section: Clinical Policies Institutional Handbook of Operating Procedures Policy 09.13.28 Responsible Vice President: EVP & CEO Health System Subject: Patient Risk, Treatment, and Safety Responsible Entity: